Testing a new drug for Alzheimer's (NTRX-07)
Part of Brain & nervous system, Mental health clinical trials.
This study tests an experimental drug for Alzheimer's called NTRX-07. It aims to see if it can slow memory decline for people with mild to moderate Alzheimer's.
Summary written for real people, not researchers, by Clin2.
Who can take part
- Age 65 to 80 years old.
- Has mild to moderate memory loss (confirmed by a short memory test).
- A blood test or brain scan that suggests Alzheimer's (within the last 2 years).
- Living at home with a caregiver who can help with study medicine and visit the clinic.
- Stable on current Alzheimer's medications (no changes for 6 months).
- No other major health problems like heart or liver disease, or a different cause for memory loss.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests a new drug called NSC001 for people with mild to moderate Alzheimer's. It checks if the drug is safe and if it might help slow memory decline. You'll need a caregiver who can join you at visits and help track your progress.
This study tests an investigational drug called BEY2153 for people with early Alzheimer's disease. It aims to see if the drug is safe and can help slow memory decline.
This study tests a new medicine, NVP-NK4146, for people with mild cognitive impairment (MCI) due to Alzheimer's disease. The goal is to see if it can help slow down memory and thinking problems.
This study tests a new medication, CORT108297, that may help protect the brain from the harmful effects of stress in people at risk for Alzheimer's disease. It is looking for adults age 55 and older who either have mild memory problems or are healthy but have a family history, APOE4 gene, or memory concerns.
This study tests a new drug called TML-6 for people with early Alzheimer's disease or mild cognitive impairment. It aims to see if the drug is safe and can help slow down memory and thinking problems.
This trial provides continued access to an investigational drug (TRx0237) for people with early or mild-moderate Alzheimer's disease. It aims to see if long-term use is safe and beneficial.
Hear when a new Mild Cognitive Impairment trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.